Skip to main content

Advertisement

SpringerLink
Log in

Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”

  • Reply
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hindie E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin’s lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017;44:1254–7.

    Article  CAS  PubMed  Google Scholar 

  2. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–8.

    Article  CAS  PubMed  Google Scholar 

  3. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34:1175–81.

    Article  CAS  PubMed  Google Scholar 

  4. Adams HJ, Kwee TC. Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2017. doi:10.1007/s00259-017-3771-8.

    Google Scholar 

  5. Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454–63.

    Article  CAS  PubMed  Google Scholar 

  6. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  CAS  PubMed  Google Scholar 

  7. Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58:577–83.

    Article  PubMed  Google Scholar 

  8. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5.

    Article  CAS  PubMed  Google Scholar 

  9. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43.

    Article  CAS  PubMed  Google Scholar 

  10. Filippi AR, Botticella A, Bello M, Botto B, Castiglione A, Gavarotti P, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma. 2013;54:1183–7.

    Article  CAS  PubMed  Google Scholar 

  11. Jalali A, Ha FJ, Chong G, Grigg A, McKendrick J, Schwarer AP, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016;95:809–16.

    Article  CAS  PubMed  Google Scholar 

  12. Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, et al. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1620–7.

    Article  PubMed  Google Scholar 

  13. Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma. 2012;53:64–70.

    Article  CAS  PubMed  Google Scholar 

  14. Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175:652–60.

    Article  PubMed  Google Scholar 

  15. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: a systematic review. J Nucl Med. 2008;49:13–21.

    Article  PubMed  Google Scholar 

  17. Adams HJ, Nievelstein RA, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95:1–9.

    Article  CAS  PubMed  Google Scholar 

  18. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4–12.

    Article  PubMed  Google Scholar 

  19. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol. 2014;32:2705–11.

    Article  PubMed  Google Scholar 

  20. Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–95.

    Article  Google Scholar 

  21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  22. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017. doi:10.1093/annonc/mdx097.

    Google Scholar 

  24. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15:608–38.

    Article  Google Scholar 

  25. Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173:236–44.

    Article  CAS  PubMed  Google Scholar 

  26. Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.

    Article  PubMed  Google Scholar 

  27. El-Galaly TC, d’Amore F, Mylam KJ, de Nully Brown P, Bogsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14.

    Article  PubMed  Google Scholar 

  28. Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, Soares J Jr, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28:1415–21.

    Article  PubMed  Google Scholar 

  29. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94.

    Article  CAS  PubMed  Google Scholar 

  30. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125–32.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France

    Elif Hindié & Charles Mesguich

  2. Hôpital Haut-Lévêque, Avenue Magellan, 33604, Pessac, France

    Elif Hindié

  3. Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France

    Krimo Bouabdallah & Noël Milpied

Authors
  1. Elif Hindié
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Mesguich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krimo Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noël Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Hindié.

Additional information

This reply refers to the letter to the editor at doi:10.1007/s00259-017-3771-8.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hindié, E., Mesguich, C., Bouabdallah, K. et al. Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”. Eur J Nucl Med Mol Imaging 44, 1937–1939 (2017). https://doi.org/10.1007/s00259-017-3773-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3773-6

Search

Navigation